Dr. Leen Kawas, managing general partner at Propel Bio Partners, illustrates how biomarkers work alongside AI and machine learning to alleviate healthcare limitations and issues
Artificial intelligence (or AI) and machine learning (ML) (a form of AI) are becoming relevant and significant in the biotech and life science industry. AI capabilities are integral to more accurate diagnostics, personalized patient treatment, and chronic disease prediction, among other applications. AI and ML are anticipated to have the most transformative effect on pharmaceutical research and development (R&D).